AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
AIM ImmunoTech Inc. (NYSE American: AIM) has announced new pre-clinical data on its drug Ampligen as part of a combination therapy for melanoma treatment. The study, published in the journal Vaccines, shows that combining dendritic cell-based vaccines with anti-PD-L1 checkpoint inhibitors and Ampligen-containing chemokine modulation helped slow tumor cell growth and improved survival in a mouse model.
Dr. David Strayer, AIM's Medical Officer, stated that this data further demonstrates Ampligen's therapeutic potential when used with dendritic-cell vaccines, anti-PD-L1 checkpoint inhibitors, or in combination with both. The company believes this supports their ongoing development of Ampligen as an anti-tumor therapy.
AIM ImmunoTech Inc. (NYSE American: AIM) ha annunciato nuovi dati pre-clinici sul suo farmaco Ampligen come parte di una terapia combinata per il trattamento del melanoma. Lo studio, pubblicato nella rivista Vaccines, mostra che combinare vaccini basati su cellule dendritiche con inibitori del checkpoint anti-PD-L1 e modulazione delle chemokine contenenti Ampligen ha aiutato a rallentare la crescita delle cellule tumorali e ha migliorato la sopravvivenza in un modello murino.
Il dott. David Strayer, medico di AIM, ha dichiarato che questi dati dimostrano ulteriormente il potenziale terapeutico di Ampligen quando utilizzato con vaccini a base di cellule dendritiche, inibitori del checkpoint anti-PD-L1, o in combinazione con entrambi. L'azienda crede che ciò supporti il loro continuo sviluppo di Ampligen come terapia anti-tumorale.
AIM ImmunoTech Inc. (NYSE American: AIM) ha anunciado nuevos datos preclínicos sobre su medicamento Ampligen como parte de una terapia combinada para el tratamiento del melanoma. El estudio, publicado en la revista Vacunas, muestra que combinar vacunas basadas en células dendríticas con inhibidores de checkpoint anti-PD-L1 y modulación de quimiocinas que contienen Ampligen ayudó a ralentizar el crecimiento de células tumorales y mejoró la supervivencia en un modelo de ratón.
El Dr. David Strayer, médico de AIM, afirmó que estos datos demuestran aún más el potencial terapéutico de Ampligen cuando se utiliza con vacunas de células dendríticas, inhibidores de checkpoint anti-PD-L1, o en combinación con ambos. La empresa cree que esto respalda su desarrollo continuo de Ampligen como una terapia anti-tumoral.
AIM ImmunoTech Inc. (NYSE American: AIM)은 멜라노마 치료를 위한 병합 요법의 일환으로 Ampligen에 대한 새로운 Pre-clinical 데이터를 발표했습니다. Vaccines 저널에 발표된 이 연구는 수지상 세포 기반 백신을 항-PD-L1 체크포인트 억제제 및 Ampligen이 포함된 케모카인 조절과 결합하면 종양 세포 성장 속도를 늦추고 생존율을 개선하는 데 도움이 되었음을 보여줍니다.
AIM의 의학 책임자인 David Strayer 박사는 이 데이터가 수지상 세포 백신, 항-PD-L1 체크포인트 억제제, 또는 두 가지 모두와 함께 사용될 때 Ampligen의 치료 잠재력을 추가로 입증한다고 밝혔습니다. 회사는 이것이 항종양 치료제로서 Ampligen의 지속적인 개발을 뒷받침한다고 믿고 있습니다.
AIM ImmunoTech Inc. (NYSE American: AIM) a annoncé de nouvelles données précliniques sur son médicament Ampligen dans le cadre d'une thérapie combinée pour le traitement du mélanome. L'étude, publiée dans le journal Vaccines, montre que la combinaison de vaccins basés sur des cellules dendritiques avec des inhibiteurs de point de contrôle anti-PD-L1 et la modulation des chimiokines contenant Ampligen a contribué à ralentir la croissance des cellules tumorales et à améliorer la survie dans un modèle murin.
Le Dr David Strayer, médecin d'AIM, a déclaré que ces données démontrent davantage le potentiel thérapeutique d'Ampligen lorsqu'il est utilisé avec des vaccins à base de cellules dendritiques, des inhibiteurs de point de contrôle anti-PD-L1, ou en combinaison avec les deux. L'entreprise croit que cela soutient leur développement continu d'Ampligen en tant que thérapie anti-tumorale.
AIM ImmunoTech Inc. (NYSE American: AIM) hat neue präklinische Daten zu seinem Medikament Ampligen als Teil einer Kombinationstherapie zur Behandlung von Melanomen bekannt gegeben. Die in der Zeitschrift Vaccines veröffentlichte Studie zeigt, dass die Kombination von dendritischen Zell-basierten Impfstoffen mit anti-PD-L1-Checkpoint-Inhibitoren und chemokinmodulierendem Ampligen das Tumorwachstum verlangsamte und die Überlebensrate in einem Mausmodell verbesserte.
Dr. David Strayer, medizinischer Direktor von AIM, erklärte, dass diese Daten das therapeutische Potenzial von Ampligen in Kombination mit dendritischen Zellimpfstoffen, anti-PD-L1-Checkpoint-Inhibitoren oder in Kombination mit beiden weiter demonstrieren. Das Unternehmen ist überzeugt, dass dies ihre fortlaufende Entwicklung von Ampligen als anti-tumorale Therapie unterstützt.
- New pre-clinical data shows Ampligen's potential in combination therapy for melanoma treatment
- Combination therapy including Ampligen helped slow tumor cell growth and improved survival in mouse models
- Results support AIM's ongoing development of Ampligen as an anti-tumor therapy
- None.
Insights
The new pre-clinical data on Ampligen's anti-tumor potential in combination with dendritic cell-based vaccines and anti-PD-L1 checkpoint inhibitors is quite significant. This data indicates enhanced tumor cell growth inhibition and improved survival rates in a mouse model, which is a promising step towards effective melanoma treatments. Given that melanoma can be very aggressive, any advancement in treatment options is noteworthy. The combination approach could potentially address the tumor microenvironment more effectively, which is a critical factor in cancer treatments.
However, it's essential to recognize that these are pre-clinical results. While promising, further clinical trials in humans will be required to confirm these findings. Investors should watch for updates on clinical trial progress and FDA feedback to gauge the therapeutic potential and market viability.
From a financial perspective, positive pre-clinical data can bolster investor confidence in AIM ImmunoTech, potentially driving up the stock price in the short term. The publication in a peer-reviewed journal adds credibility and could attract more institutional investors or partnerships. However, investors should be cautious and not overestimate the immediate financial impact. Pre-clinical results are just one step in a long and uncertain journey towards market authorization and commercial success. Long-term value will depend on successful clinical trials, regulatory approvals and eventual market adoption.
It's also worth noting that the biopharma sector is highly volatile and driven by such news. While this announcement is a positive indicator, investors should consider the company's broader pipeline, financial health and strategic partnerships.
As an oncology expert, the findings from AIM ImmunoTech are exciting. The combination of dendritic cell-based vaccines with anti-PD-L1 checkpoint inhibitors and chemokine modulation is a novel approach in the fight against melanoma. Dendritic cell vaccines are designed to stimulate the body's immune response against cancer cells, while checkpoint inhibitors like anti-PD-L1 help to unleash the immune system to attack the tumor. Ampligen's role in modulating the chemokine environment could enhance these effects, leading to better patient outcomes.
Nonetheless, transitioning from pre-clinical models to human trials presents numerous challenges. The immune system's complexity means that results in mice may not always replicate in humans. Close monitoring of future clinical trials will be important for determining if these pre-clinical successes translate into real-world therapeutic benefits.
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the treatment of melanoma, showing that combination dendritic cell-based vaccines including anti-PD-L1 checkpoint inhibitors and Ampligen-containing chemokine modulation helped slow tumor cell growth and improved survival in a mouse model.
“Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1” was published in the peer-reviewed journal Vaccines.
AIM Medical Officer David Strayer, MD, stated: “This new pre-clinical data further demonstrates Ampligen’s therapeutic potential when used with dendritic-cell vaccines, with anti-PD-L1 checkpoint inhibitors, or in combination with both. The data supports AIM’s belief that we are on the right path in our ongoing development of Ampligen as an anti-tumor therapy.”
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Publication of this data, and pre-clinical and clinical success seen to date, does not guarantee that Ampligen will be approved for the commercial treatment of cancers. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
FAQ
What new data did AIM ImmunoTech (AIM) announce about Ampligen?
How did the combination therapy with Ampligen perform in the AIM study?
What did AIM's Medical Officer say about the new Ampligen data?
Where was the AIM ImmunoTech (AIM) Ampligen study published?
